Bladder cancer
Conditions
Interventions
Observation group:None
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age= 18 years old; 2. Bladder cancer diagnosed with histopathology; 3. Planned to receive bladder-sparing radiotherapy at the Department of Oncology Radiotherapy, Peking University Third Hospital; 4. The investigator assesses the subject's general health status based on their medical history, physical examination, and vital signs.
Exclusion criteria
Exclusion criteria: 1. Having central nervous system metastases and/or cancerous meningitis. 2. Other serious, uncontrollable comorbidities that may affect protocol adherence or interfere with interpretation of results, including active opportunistic infections or advanced (severe) infections, uncontrolled diabetes, uncontrolled hypertension, cardiovascular diseases (heart failure classified as grade III or IV by the New York Heart Association, heart block of grade II or above, myocardial infarction within the past 12 months, unstable arrhythmias or unstable angina, cerebral infarction within 6 months, etc.) or lung diseases (interstitial pneumonia, History of obstructive pulmonary disease and symptomatic bronchospasm), and the occurrence of deep vein thrombosis or pulmonary embolism within the past 6 months; 3. Having other malignant tumors within the previous 5 years prior to enrollment, except for the following cases: Patients with localized low-risk prostate cancer (defined as stage = T2b, Gleason score =7, and PSA =20ng/mL at diagnosis (as measured) who have received curative treatment and have not had prostate-specific antigen (PSA) recurrence may participate in this study; Malignant tumors expected to heal after treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ after radical surgery); 4. Pregnant or breastfeeding women; 5. HIV test result is positive; 6. Patients with active hepatitis B or C; 7. History of active tuberculosis; 8. Having any other diseases, metabolic abnormalities, physical examination abnormalities, or laboratory abnormalities, where, based on the investigator's judgment, there is reason to suspect the patient has a disease or condition unsuitable for use of the investigational drug, which may affect the interpretation of study results or place the patient at high risk; 9. Estimated insufficient compliance with participation in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progress in survival; | — |
Countries
China
Contacts
Public ContactWang Hao
Peking University Third Hospital
Outcome results
None listed